KR20230027213A - 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 - Google Patents

세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 Download PDF

Info

Publication number
KR20230027213A
KR20230027213A KR1020237002102A KR20237002102A KR20230027213A KR 20230027213 A KR20230027213 A KR 20230027213A KR 1020237002102 A KR1020237002102 A KR 1020237002102A KR 20237002102 A KR20237002102 A KR 20237002102A KR 20230027213 A KR20230027213 A KR 20230027213A
Authority
KR
South Korea
Prior art keywords
mmol
trans
cyclohexyl
alkyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237002102A
Other languages
English (en)
Korean (ko)
Inventor
매튜 디. 알렉산더
매튜 디. 코레아
디팍 달비
버지니아 헤더 샤론 그랜트
조슈아 한센
3세 로이 엘. 해리스
에반 제이. 호른
데후아 후앙
크리스토퍼 메인
스티븐 노리스
베로니크 플란테빈-크레니트스키
존 제이. 사피엔자
리다 테흐라니
브랜든 더블유. 화이트필드
Original Assignee
셀진 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀진 코포레이션 filed Critical 셀진 코포레이션
Publication of KR20230027213A publication Critical patent/KR20230027213A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020237002102A 2020-06-24 2021-06-23 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 Pending KR20230027213A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043612P 2020-06-24 2020-06-24
US63/043,612 2020-06-24
PCT/US2021/038625 WO2021262812A1 (en) 2020-06-24 2021-06-23 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
KR20230027213A true KR20230027213A (ko) 2023-02-27

Family

ID=79032406

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237002102A Pending KR20230027213A (ko) 2020-06-24 2021-06-23 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법

Country Status (9)

Country Link
US (2) US11739075B2 (cg-RX-API-DMAC7.html)
EP (1) EP4171568B1 (cg-RX-API-DMAC7.html)
JP (1) JP7778095B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230027213A (cg-RX-API-DMAC7.html)
CN (1) CN115955979B (cg-RX-API-DMAC7.html)
AR (1) AR122725A1 (cg-RX-API-DMAC7.html)
ES (1) ES3048462T3 (cg-RX-API-DMAC7.html)
TW (1) TW202216681A (cg-RX-API-DMAC7.html)
WO (1) WO2021262812A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
IL299256A (en) 2020-06-24 2023-02-01 Celgene Corp Cerebellum binding compounds, their compounds and methods of treatment with them
ES3047718T3 (en) 2020-06-24 2025-12-04 Celgene Corp Cereblon binding compounds, compositions thereof, and methods of treatment therewith
WO2022262782A1 (zh) * 2021-06-17 2022-12-22 南京明德新药研发有限公司 戊二酰亚胺取代的异噁唑稠环化合物及其应用
US20240408085A1 (en) 2021-09-01 2024-12-12 Xizang Haisco Pharmaceutical Co., Ltd. Compound for degradation of bcl-2 family proteins and medical application thereof
KR20250020448A (ko) 2022-06-02 2025-02-11 시젱 하이스코 파마수티칼 씨오., 엘티디. Bcl6을 억제하거나 분해하는 화합물 및 의약학에서의 응용
TW202530189A (zh) 2023-09-29 2025-08-01 日商第一三共股份有限公司 3-苯基丙基胺衍生物
CN122497677A (zh) 2023-10-20 2026-07-31 奇树医药公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
AU2024392985A1 (en) 2023-12-08 2026-06-04 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
WO2008101030A1 (en) * 2007-02-13 2008-08-21 The Regents Of The University Of California Methods for amplifying steroid hormone effects
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
WO2015179434A1 (en) * 2014-05-20 2015-11-26 Ohio State Innovation Foundation Small molecule ras inhibitors
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN110317192A (zh) * 2018-03-28 2019-10-11 上海美志医药科技有限公司 一类具有降解雄激素受体活性的化合物
BR112021011968A2 (pt) 2018-12-19 2021-09-08 Celgene Corporation Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
AU2019404022A1 (en) 2018-12-19 2021-07-08 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
IL299256A (en) 2020-06-24 2023-02-01 Celgene Corp Cerebellum binding compounds, their compounds and methods of treatment with them
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
ES3047718T3 (en) 2020-06-24 2025-12-04 Celgene Corp Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
EP4171568B1 (en) 2025-08-27
US11739075B2 (en) 2023-08-29
US20210403453A1 (en) 2021-12-30
WO2021262812A1 (en) 2021-12-30
ES3048462T3 (en) 2025-12-10
EP4171568A1 (en) 2023-05-03
AR122725A1 (es) 2022-09-28
JP2023531709A (ja) 2023-07-25
CN115955979B (zh) 2025-12-05
US12227490B2 (en) 2025-02-18
JP7778095B2 (ja) 2025-12-01
US20230348431A1 (en) 2023-11-02
EP4171568A4 (en) 2024-07-24
CN115955979A (zh) 2023-04-11
TW202216681A (zh) 2022-05-01

Similar Documents

Publication Publication Date Title
EP4171568B1 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
US12103920B2 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
US11560371B2 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
WO2022272074A1 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091356A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091356B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
US20250100995A1 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
KR20240025613A (ko) 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
HK40091357A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091357B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902